



The HIV Prevention Trials Network (HPTN) is a global, collaborative clinical trials network that develops and evaluates the safety and efficacy of interventions designed to prevent HIV infection. HPTN brings together researchers, community representatives and other partners to conduct clinical trials with the goal of deriving scientific evidence to guide HIV prevention programs.

Over
40 sites

More than
15 countries



Our Sponsor:

U.S. National Institutes of Health (NIH)

**National Institute of Allergy and Infectious Diseases (NIAID)
Awards UM1 AI068619, UM1AI068617, and UM1AI068613, co-funded by the National Institute of Mental Health, and the National Institute on Drug Abuse**

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, visit www.hptn.org

HPTN studies assess new HIV prevention strategies in populations and geographical regions hardest hit by the epidemic. Since its inception in 1999, the network has conducted research in more than 40 sites in more than 15 countries in sub-Saharan Africa, the Americas and Asia.



The HPTN research agenda focuses on integrated strategies that include the use of antiretroviral drugs for prevention (TasP) and pre-exposure prophylaxis (PrEP); interventions for persons who inject drugs; as well as behavioral and structural interventions. As of July 2015, there are 13 HPTN studies, either active in the field or undergoing data analysis and four studies in development addressing these research areas. These include studies evaluating integrated strategies as well as new agents for PrEP (injectable antiretroviral agents and a monoclonal antibody for HIV prevention, the latter in collaboration with the HIV Vaccine Trials Network).



HPTN has contributed to scientific breakthroughs and helped shape approaches to HIV prevention worldwide, including a landmark study demonstrating that early initiation of antiretroviral therapy (ART) dramatically reduces sexual transmission of HIV (HPTN 052), a trial demonstrating that young, single women in South Africa will adhere to a daily PrEP regimen (HPTN 067), and a trial that proved high rates of HIV testing can be achieved through a combination of integrated community-level interventions (HPTN 043).

The HPTN is led by Wafaa El-Sadr, M.D., M.P.H., director of the International Center for AIDS Care and Treatment Programs and director of the Center for Infectious Disease Epidemiologic Research CIDER at Columbia University's Mailman School of Public Health, and Myron Cohen, M.D., director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill. It is centrally managed by a Leadership and Operations Center based at FHI 360 in Durham, NC; a Laboratory Center at Johns Hopkins University in Baltimore, MD; and a Statistical and Data Management Center as part of the Statistical Center for HIV/AIDS Research and Prevention (SCHARP) at the Fred Hutchinson Cancer Research Center in Seattle, WA.